Overall treatment success after treatment of primary superficial basal cell carcinoma: A systematic review and meta-analysis of randomized and nonrandomized trials

British Journal of Dermatology

Volumn 167, Issue 4, 2012, Pages 733-756

  Roozeboom, M H ^a,b   Arits, A H H M ^a,b   Nelemans, P J ^a   Kelleners Smeets, N W J ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE; LIQUID NITROGEN;

ARGON LASER; BASAL CELL CARCINOMA; CANCER RECURRENCE; CANCER SURGERY; CRYOTHERAPY; DISEASE FREE SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; ILLUMINATION; META ANALYSIS; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PULSED DYE LASER; REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DISEASE-FREE SURVIVAL; HUMANS; PHOTOCHEMOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84867063990     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11061.x     Document Type: Review

References (62)

1. de Vries E, van de Poll-Franse LV, Louwman WJ, et al. Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol 2005; 152: 481-8.
2. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E, et al. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol 2007; 157 (Suppl. 2): 47-51.
3. Holterhues C, Vries E, Louwman MW, et al. Incidence and trends of cutaneous malignancies in the Netherlands, 1989-2005. J Invest Dermatol 2010; 130: 1807-12.
4. Bath-Hextall F, Leonardi-Bee J, Smith C, et al. Trends in incidence of skin basal cell carcinoma. Additional evidence from a U.K. primary care database study. Int J Cancer 2007; 121: 2105-8.
5. Birch-Johansen F, Jensen A, Mortensen L, et al. Trends in the incidence of nonmelanoma skin cancer in Denmark 1978-2007: rapid incidence increase among young Danish women. Int J Cancer 2010; 127: 2190-8.
6. Marcil I, Stern RS,. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000; 136: 1524-30.
7. Kiiski V, de Vries E, Flohil SC, et al. Risk factors for single and multiple basal cell carcinomas. Arch Dermatol 2010; 146: 848-55.
8. Telfer NR, Colver GB, Morton CA,. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.
9. Arits A, Schlangen M, Nelemans P, et al. Trends in the incidence of basal cell carcinoma by histopathological subtype. J Eur Acad Dermatol Venereol 2010; 25: 565-9.
10. Bath-Hextall FJ, Perkins W, Bong J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007; 1: CD003412.
11. Baptista J, Martinez C, Leite L, et al. Our PDT experience in the treatment of non-melanoma skin cancer over the last 7 years. J Eur Acad Dermatol Venereol 2006; 20: 693-7.
12. Thissen MR, Neumann MH, Schouten LJ,. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135: 1177-83.
13. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-12.
14. von Elm E,. Commentary: assessing the quality of observational studies-or a lesson from Mars. Int J Epidemiol 2007; 36: 677-8.
15. Cantor AB,. Projecting the standard error of the Kaplan-Meier estimator. Stat Med 2001; 20: 2091-7.
16. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
17. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-60.
18. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34.
19. Healy JB,. The use of topical 5-fluorouracil in the treatment of skin tumours-preliminary report. J Ir Med Assoc 1969; 62: 41-6.
20. Zouboulis CC, Blume U,. Outcomes of cryosurgery in patients with basal-cell carcinoma. Skin Cancer 1994; 9: 7-22.
21. Ezughah FI, Dawe RS, Ibbotson SH, et al. A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. J Dermatolog Treat 2008; 19: 111-17.
22. Marks R, Owens M, Walters SA,. Efficacy and safety of 5% imiquimod cream in treating patients with multiple superficial basal cell carcinomas. Arch Dermatol 2004; 140: 1284-5.
23. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-13.
24. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147: 1227-36.
25. Miller BH, Shavin JS, Cognetta A, et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. J Am Acad Dermatol 1997; 36: 72-7.
26. Siller G, Rosen R, Freeman M, et al. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol 2010; 51: 99-105.
27. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-33.
28. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47: 390-8.
29. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152: 939-47.
30. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008; 18: 547-53.
31. Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008; 22: 1302-11.
32. Schleier P, Berndt A, Kolossa S, et al. Comparison of aminolevulinic acid (ALA)-thermogel-PDT with methyl-ALA-thermogel-PDT in basal cell carcinoma. Photodiagn Photodyn Ther 2007; 4: 197-201.
33. Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144: 832-40.
34. Soler AM, Angell-Petersen E, Warloe T, et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: a comparison of two light sources. Photochem Photobiol 2000; 71: 724-9.
35. Quirk C, Gebauer K, De'Ambrosis B, et al. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis 2010; 85: 318-24.
36. Alessi SS, Sanches JA, Oliveira WR, et al. Treatment of cutaneous tumors with topical 5% imiquimod cream. Clinics (Sao Paulo) 2009; 64: 961-6.
37. Ruiz-Villaverde R, Sanchez-Cano D, Burkhardt-Perez P,. Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series. J Eur Acad Dermatol Venereol 2009; 23: 828-31.
38. Shah SM, Konnikov N, Duncan LM, et al. The effect of 595 nm pulsed dye laser on superficial and nodular basal cell carcinomas. Lasers Surg Med 2009; 41: 417-22.
39. Campolmi P, Troiano M, Bonan P, et al. Vascular based non conventional dye laser treatment for basal cell carcinoma. Dermatol Ther 2008; 21: 402-5.
40. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 2008; 18: 677-82.
41. Gross K, Kircik L, Kricorian G,. 5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg 2007; 33: 433-9; discussion 440.
42. Schiessl C, Wolber C, Tauber M, et al. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up. J Drugs Dermatol 2007; 6: 507-13.
43. Star WM, van't Veen AJ, Robinson DJ, et al. Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-term follow-up. Acta Derm Venereol 2006; 86: 412-17.
44. Vun Y, Siller G,. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Australas J Dermatol 2006; 47: 169-71.
45. Nikkels AF, Pierard-Franchimont C, Nikkels-Tassoudji N, et al. Photodynamic therapy and imiquimod immunotherapy for basal cell carcinomas. Acta Clin Belg 2005; 60: 227-34.
46. Naidenov N, Dencheva R, Tsankov N,. Recurrence rate of basal cell carcinoma after topcial aminolevulinic acid-based photodynamic therapy. Acta Dermatovenerol Croat 2004; 12: 157-61.
47. Shumack S, Gebauer K, Quirk C, et al. 5% imiquimod cream for the treatment of large superficial basal cell carcinoma. Arch Dermatol 2004; 140: 1286-7.
48. Dijkstra AT, Majoie IM, van Dongen JW, et al. Photodynamic therapy with violet light and topical 6-aminolaevulinic acid in the treatment of actinic keratosis, Bowen's disease and basal cell carcinoma. J Eur Acad Dermatol Venereol 2001; 15: 550-4.
49. Langmack K, Mehta R, Twyman P, et al. Topical photodynamic therapy at low fluence rates-theory and practice. J Photochem Photobiol B 2001; 60: 37-43.
50. Haller JC, Cairnduff F, Slack G, et al. Routine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy. Br J Dermatol 2000; 143: 1270-5.
51. Humphreys TR, Malhotra R, Scharf MJ, et al. Treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ with a high-energy pulsed carbon dioxide laser. Arch Dermatol 1998; 134: 1247-52.
52. Hurlimann AF, Hanggi G, Panizzon RG,. Photodynamic therapy of superficial basal cell carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion. Dermatology 1998; 197: 248-54.
53. Wennberg AM, Lindholm LE, Alpsten M, et al. Treatment of superficial basal cell carcinomas using topically applied delta-aminolaevulinic acid and a filtered xenon lamp. Arch Dermatol Res 1996; 288: 561-4.
54. Cairnduff F, Stringer MR, Hudson EJ, et al. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer 1994; 69: 605-8.
55. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. Br J Dermatol 1994; 130: 743-51.
56. Challacombe JM, Suhrbier A, Parsons PG, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 2006; 177: 8123-32.
57. Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. Br Med J 2009; 338: b1147.
58. Ezughah FI, Affleck AG, Evans A, et al. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream. J Dermatolog Treat 2008; 19: 156-8.
59. de Haas ER, Kruijt B, Sterenborg HJ, et al. Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. J Invest Dermatol 2006; 126: 2679-86.
60. Quirk C, Gebauer K, Owens M, et al. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol 2006; 47: 258-65.
61. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol 2005; 15: 374-81.
62. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Methyl aminolevulinate photodynamic therapy versus cryotherapy in primary superficial basal cell carcinoma: results of a 36 month follow-up. Br J Dermatol 2005; 30: 29.